Chronic Cluster Headache
Conditions
Keywords
Cluster Headaches
Brief summary
The purpose of this clinical trial is to evaluate the safety and effectiveness of the Occipital Nerve Stimulation System (ONSS) in treating chronic cluster headache in adults. The study aims to answer the following questions: * What adverse events or medical complications occur following ONSS implantation and stimulation? * Does treatment with the ONSS reduce the frequency of cluster headache attacks compared with baseline? Participant Involvement Participants will: * Undergo implantation of the ONSS device. * Use the ONSS for a 48-week treatment period. * Attend scheduled clinic visits for follow-up assessments and device evaluations. * Maintain a diary documenting cluster headache attacks and use of rescue medications. * Complete study-related assessments throughout the study period.
Interventions
DEVICEOccipital Nerve Stimulation System
48 weeks of daily stimualtion with ONS System
Sponsors
Man and Science, SA
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
22 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. ICHD-3 criteria for chronic cluster headache 2. Documented history of CCH since at least 1 year 3. Minimum mean attack frequency of 4 attacks per week at baseline (-4week to +2 week up to implant) 4. Documented minimum 4 weeks of retrospective cluster headache diary data 5. Age range: 22-70 years 6. Difficult-to-treat CCH with documented previous complete failure, insufficient efficacy, intolerance, or contra-indications to most preventive CH treatments among which are oral steroids or suboccipital infiltrations, verapamil, lithium carbonate and topiramate. 7. No preventive CH treatment or stable preventive CH medication for ≥ 2 weeks before enrolment. Subject agrees not to change existing treatment during the whole duration of the trial. 8. Participant written informed consent provided before enrolment 9. Participant willing and capable of subjective evaluation and to fill in an electronic CH diary, to understand questionnaires, and to read, understand and sign the written informed consent form. 10. Partcipant willing and able to comply with study-related requirements, procedures, and visits.
Exclusion criteria
1. Other significant neurological, psychiatric, or disabling diseases which in the opinion of the investigator may interfere with the study. 2. History of epilepsy, current treatment of epilepsy 3. Documented history of cerebrovascular accident (CVA) 4. Participants suffering from a substance use disorder, as defined by Diagnostic and Statistical Manual of Mental Disorders (DSM) criteria. Recreational use of cannabis is allowed. 5. Participants at high risk of suicide/suicidal ideation in the past one year assessed with the C-SSRS at screening 6. Having another active implanted device such as a cardiac pacemaker, a spinal cord, peripheral nerve, sphenopalatine ganglion, or deep brain hypothalamic stimulator, and/or a drug delivery pump, etc. 7. Cranial botulinum toxin injections in the past 3 months before enrolment. Administration of the following treatments in the last month before enrolment: monoclonal antibodies blocking calcitonin gene-related peptide transmission, suboccipital infiltrations with steroids and/or local anesthetics, oral steroids, radiofrequency procedure or infiltrations of the sphenopalatine ganglion, opioids WHO 3. Oral or systemic steroids are not allowed during the month before enrolment, except low doses (prednisone not superior to 10mg/day for no more than 7 days) if needed for other disorders. 8. Medication overuse headache (ICHD 3 8.2) 9. Inability to fill out an electronic diary. 10. Previous surgery or trauma involving the cervical spine or the occipital bone 11. Coagulopathy or required anticoagulant medications that cannot be safely discontinued in the perioperative period. 12. Concurrent participation in another clinical study 13. Planned pregnancy, pregnancy, or breastfeeding.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of procedure-related or device-related adverse events at 12 weeks | From implantation to 12 weeks post implantation |
| Number of adverse events at 48 weeks | From implantation to 48 weeks post-activation |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in the mean weekly attack frequency | From enrollment to 48 weeks post-activation | — |
| 50% Responder rate | From enrollment to 48 weeks post-activation | Proportion of subjects achieving a ≥ 50% reduction in mean weekly attack frequency compared to baseline |
| 30% Responder rate | From enrollment to 48 weeks post-activation | Proportion of subjects achieving a ≥ 30% reduction in mean weekly attack frequency compared to baseline |
| Change in the mean weekly attack intensity compared to baseline | From enrollment to 48 weeks post-activation | Intensity is assessed using a 5-point ordinal pain scale from 0-no pain to 4-the worst pain |
| Change in the mean number of weekly attack treatments compared to baseline | From enrollment to 48 weeks post-activation | Attack treatments include but are not limited to triptan injections or nasal sprays or pills, 02 inhalations |
| Scalp distribution of stimulation-induced paraesthesia per scalp region assessed using an 18-region scalp mapping tool | From enrollment to 48 weeks post-activation | Scalp distribution of stimulation-induced paraesthesia will be assessed weekly and recorded in the participant's electronic diary. Participants will indicate the location(s) of perceived paraesthesia on a standardized scalp map divided into 18 predefined regions. The distribution will be quantified as the percentage of reported paraesthesia across these regions. |
Countries
Belgium
Contacts
CONTACTChristelle Nguepi
Outcome results
None listed